Keylika is an early stage biopharma startup developing organometallic drugs using a proprietary platform synthesis technology, to treat unmet medical needs. We then administer these drugs using proven delivery technologies, to effect the best clinical outcomes. Positioned at the intersection of drug discovery and drug delivery, enables us to customize the molecular structure and/or formulation of a drug as well as the microsystems engineering component to optimally fit the most clinically advantageous mode of drug delivery. Our first product is a novel iron complex (new molecular entity) administered by a wearable transdermal patch. This is slated to be a best-in-class, breakthrough therapy for treating Iron Deficiency Anemia (IDA) without any GI side-effects (eg. nausea, constipation, diarrhoea, etc.) typically associated with oral iron supplements, and without risks associated with IV iron infusions. Eventually, this may serve to replace both oral as well as parenteral IV iron forms. Preliminary animal studies have shown excellent results. Our first target population is young women of child-bearing age suffering from heavy menstruation or menorrhagia and thus, severe IDA (population size: 6 million in the US). Iron deficiency is an understated problem affecting 30 million people in the US alone and 1.6 billion worldwide, with grossly suboptimal current solutions. Recently, we have been accepted at Y Combinator for the Summer 2022 cohort (starting in June).
